Natalizumab, which is an antibody against α4 integrin, has been used for the treatment of multiple sclerosis (MS). In the present study, we investigated both the role of α4 integrin and the therapeutic effect of HCA3551, a newly synthesized orally active small-molecule α4 integrin antagonist, in the development of TMEV-induced demyelinating disease (TMEV-IDD). The mRNA levels of α4 integrins were significantly up-regulated in the CNS of mice with TMEV-IDD as compared with naïve mice (*p<0.05). HCA3551 treatment in the effector phase significantly suppressed both the clinical and histological development of TMEV-IDD. The number of infiltrating mononuclear inflammatory cells in the CNS was significantly decreased in the mice treated with HCA3551 (**p<0.01). The labeling indices for CD68 antigen and the absolute cell numbers of TNF-α-producing CD4 + T cells and IFN-γ-producing CD8 + T cells were significantly decreased in the CNS of mice treated with HCA3551 (*p<0.05). HCA3551 treatment in the effector phase might inhibit the binding of α4 integrin to VCAM-1, thereby decreasing the number of MNCs in the CNS. Keywords: α4 integrin, α4 integrin inhibitor, multiple sclerosis, Theiler's murine encephalomyelitis virus (TMEV), TMEV-induced demyelinating disease (TMEV-IDD)
Introduction
Multiple sclerosis (MS) is an immune-mediated chronic demyelinating disease that is associated with inflammation in the white matter of the human central nervous system (CNS).
Histologically, MS is characterized by CNS lesions displaying inflammation, demyelination and axonal damage. Although its etiology remains unclear, MS is generally considered to be an autoimmune disease mediated by T helper (Th) 1 and Th 17 cells (1, 2) . The morphology of the acute lesion and the susceptibility to MS that is apparently conferred through certain MHC class II-restricted antigens suggest that autoreactive CD4 + T cells play a crucial role in the disease process.
Moreover, CD8 + T cells might participate in the pathogenesis of MS based on animal models of this disease (3, 4) . Epidemiological evidence suggests that one or more infectious agents might be involved in the initial tissue damage, leading to autoimmunity. Evidence indicates that infection with the Epstein-Barr virus plays a major role in the pathogenesis of MS, although precise role for this virus remains incompletely understood (5, 6) . Several virus-induced and autoimmune models have been used to examine the underlying mechanisms of this disease (7) (8) (9) (10) . In particular, Theiler's murine encephalomyelitis virus (TMEV)-IDD provides an excellent infectious model for several reasons (9, 11 ).
Theiler's murine encephalomyelitis virus (TMEV) is a positive sense single-stranded RNA (ssRNA) virus of the Picornaviridae family (12) . The infection of TMEV in CNS induces immune-mediated demyelinating disease in susceptible mouse strains. TMEV-induced demyelinating disease (TMEV-IDD) serves as a relevant infectious animal model for human MS, because this disease displays histopathological, genetic and clinical similarities to human MS. In addition, the development and progression of TMEV-IDD well correlated with the level of Th 1 responses specific for viral epitopes (13) (14) (15) .
The α4 integrins impact hematopoiesis, leukocyte trafficking in immune surveillance and inflammation, and leukocyte activation and survival (16) . α4 integrin, which is expressed on the surface of leukocytes, pairs with one of two β subunits, : β1 and β7 (17) . α4β1 integrin primarily binds to vascular cell adhesion molecule-1 (VCAM-1) and the CS1 fragment of fibronectin (18) .
Specifically, the interaction of α4β1/VCAM-1 plays a major role in the recruitment of mononuclear leukocytes to inflammatory sites in vivo (19) . Anti-α4 integrin antibody significantly suppressed the development of paralysis and the infiltration of leukocytes into the CNS in rat experimental autoimmune encephalomyelitis (EAE) (20) . Anti-α4 integrin antibody suppressed the clinical score and pathological features of EAE in the guinea pigs by inhibiting leukocyte infiltration into the CNS (21) . In addition, magnetic resonance imaging revealed that an antibody against α4 integrin significantly decreased the percentage of pixels as a result of the leakage of contrast material and CNS abnormalities associated with cerebral edema and inflammation compared with control animals of guinea pig EAE (22) . In a placebo-controlled trial involving 213 patients with relapsing-remitting or relapsing secondary progressive MS, treatment with natalizumab, an antibody against α4 integrin, showed a marked suppression of the mean number of new lesions and relapses compared with the placebo-group (23) . However, progressive multifocal leukoencephalopathy (PML) has been reported 5 / 38 in MS and Crohn's disease patients who are treated with natalizumab (24) (25) (26) . In the present study, we investigated the role of α4 integrin and the effects of orally active small molecules α4 integrin antagonists in the development of TMEV-IDD, which is an infectious animal model for MS.
Here, we demonstrated that the mRNA levels of α4 integrins were significantly up-regulated in the development and treatment of TMEV-IDD with the newly synthesized orally active small molecule α4 integrin antagonist, HCA3551, which markedly suppressed the development of TMEV-IDD.
Methods

Mice
Female SJL/J mice, at 6 weeks old, were purchased from Charles River Laboratories, Inc.
(Ibaraki, Japan) and, housed and maintained for in an approved facility, in accordance with the Shinshu University Guide for Laboratory. The animals were housed in aluminum cages containing pine chips and fed food and water ad libitum. The protocol for animal experiments was approved through the Animal Care Committee of Shinshu University.
Virus
The BeAn strain of TMEV was expanded in baby hamster kidney (BHK) cells in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 7% donor calf serum (Life Technologies, Gaithersburg, MD, USA). Cell lysates with known plaque forming units (PFU) were used as viral stocks for animal experiments. Partially purified virus was prepared following centrifugation through 30% sucrose as previously described and used for in vitro assays (27). The viral titer was determined using a standard plaque assay on BHK cells.
Infection of mice with TMEV
The mice were intracerebrally (i.c.) infected with 30 μl (0.6710 6 PFU) of the BeAn strain of TMEV on day 0, and clinically observed and scored from day 0 to the end of the experiments. The mice were examined daily for clinical neurological signs, scored and recorded using the following grading scale: grade 0 = no clinical signs; grade 1 = mild waddling gait; grade 2 = moderate waddling gait and hindlimb paresis; grade 3 = severe hindlimb paralysis; grade 4 = severe hindlimb paralysis and loss of righting reflex; and grade 5 = moribund or death. Two independent investigators, who were blinded to the treatment of each animal, assessed the clinical score. The cumulative clinical score was calculated for the individual mice in each group.
In vivo blockade of α4 integrins
Six-week-old female SJL/J mice were separated into groups (Table 1 ). TMEV was injected (i.c.) into SJL/J mice i.c. on day 0. To block α4 integrins, we used HCA3551 (Ajinomoto Pharmaceuticals Co., Ltd, Tokyo, Japan) an orally active small molecule antagonist that inhibits the binding of α4β1 integrin to VCAM-1, but not αLβ2 integrin to ICAM-1. The IC50 values were 8.2 and >5,000 nM, respectively. In addition, the inhibitory activity of HCA3551 was not reduced after adding 50% human serum (IC; 11nM), although the inhibitory activity of the α4 integrin antagonist, afirategrast (GlaxoSmithKline Co., UK) was dramatically reduced (28). HCA3551 was dissolved in 0.5% hydroxypropyl methyl cellulose (methylcellulose) (Sigma-Aldrich, St Louis, MO, USA) as vehicle. The BeAn strain of TMEV induces a clinically undetectable level of early-phase disease, whereas the DA strain of TMEV induces significant polio-like symptoms (29). We used the BeAn strain of TMEV in previous studies, specifically a recent batch of the BeAn strain, which causes early onset TMEV-IDD. The onset of TMEV-IDD occurred at approximately 14 days post-infection using this batch of the BeAn strain of TMEV (30). Therefore, the mice were treated with 100 mg/kg HCA3551 twice a day via oral gavage from 11 to 40 days post infection (dpi) or at 41 dpi in the effector phase (group B and E, respectively) and from -3 to 14 dpi in the induction phase (group D).
In a preliminary study, to evaluate the efficacy of HCA3551, HCA3551 was dissolved in 0.5% methylcellulose and orally administered at doses of 30, 100, and 300 mg/kg BID twice a day to female SCID mice to generate a mouse model of colitis through the adoptive transfer of CD4+ T cells from diseased IL-10 -/mice at Ajinomoto pharmaceuticals. HCA3551 suppressed the severity of the mouse model of colitis in a dose-dependent manner. The inhibition of the severity of mouse colitis was statically significant in experimental groups treated with HCA3551 at doses of 30, 100 and 300 mg/kg. However, there was no significant difference between the 100 and 300 mg/kg doses (data not shown). Therefore, we assessed the effects of the 100 mg/kg dosage of HCA3551. Control groups (group A and C) were treated with 0.5% methylcellulose/H 2 O as a vehicle during the same 8 / 38
interval. The mice were sacrificed at 40 dpi in experiment 1 and at 41 dpi in the experiment 2. The details of the experimental design are shown in Table1 and all mice were subjected to essentially identical manipulations.
Gene expression measurements
Total RNA was extracted from the CNS (brain and spinal cord) using TRIzol ( Table 2 . The primers for β-actin (Mm01205647_g1) were obtained from Applied Biosystems. Amplification was conducted in a total volume of 10 μl for 40 cycles of 15 s at 95°C, 30 s at 60°C and 30 s at 72°C for α4 integrin and β-actin, and for 40 cycles of 1 s at 95°C and 20 s at 60°C for TMEV and β-actin. The mRNA levels were determined after normalizing the RNA concentration against β-actin.
CNS mononuclear cell isolation
Infiltrating mononuclear cells (MNCs) in the CNS (brain and spinal cord) were isolated 9 / 38 according to the method of Michael A. Lyman (31). Briefly, sterile Hanks' balanced salt solution (30 ml) was injected through the left ventricle of the heart to perfuse the CNS. The CNS was subsequently removed, forced through a cell strainer, and single-cell suspensions were prepared according to standard methods. Briefly, a Percoll-NaCl solution was prepared by the addition of 9 parts (v/v) Percoll (GE Healthcare, Little Chalfont, UK) to 1 part (v/v) 1.5 M NaCl solution. The CNS cell suspensions were centrifuged at 300g for 5 min and resuspended in 5 ml of 37% Percoll-NaCl solution diluted with culture medium and overlaid onto 2.5 ml of 70% Percoll-NaCl solution diluted with culture medium. The gradient was centrifuged at 2,000g for 20 min and the MNCs were harvested from the 37%-70% interface, followed by washing and counting.
Flow cytometry
For intracellular staining, MNCs isolated from the CNS were stimulated for 6 hours at 37°C in culture medium containing VP2 70-86 (MHC class II-restricted immundominant peptide for CD4 + T cells: WTSQEAFSHIRIPLP; Operon, Tokyo, Japan) or VP3 159-166 (MHC class I-restricted immundominant peptide for CD8 + T cells: FNFTAPFI; Operon) of TMEV (5 M for each peptide) and brefeldin A (10 μg/ml; Sigma, St. Louis, MO), in a humidified 5% CO 2 atmosphere. The MNCs were washed and triple-or double-labeled with FITC-conjugated anti-mouse IFN- or TNF-α mAb, PE-conjugated anti-mouse IL-4, IL-10 or IL-17A mAb and PerCP-conjugated anti-mouse CD4 or CD8 mAb for 30 min at room temperature in the dark. All antibodies were obtained from BD Biosciences (San Diego, USA). After washing, the cells were analyzed on a FACSCanto II Flow Cytometer (BD Biosciences).
Histology
The mice were sacrificed for histological examination at 40 dpi (group A and B). Subsequently, the spinal cords were removed and fixed as previously described (32) . Spinal cord sections from paraffin-embedded tissues were prepared at thickeness of 3-or 6-μm. The sections were stained Furthermore, we adopted labeling indices (LIs) to more quantitatively show the positive cells. The
The LIs for CD3, a T cells marker, CD45R, a B cells marker, and CD68, a macrophages markers, were examined in the same serial sections and photographed using a light microscope at a magnification of ×200 in three randomly selected fields. Using the photographs, we examined at 
Statistical analysis
Comparisons were performed with the Mann-Whitney U-test using JMP software (SAS institute Inc., Tokyo, Japan). The differences were considered statistically significant when the two-tailed p-value was <0.05.
Results
The expression of the mRNA of α4 integrin in the CNS of mice with TMEV-IDD
To investigate the mRNA levels of α4 integrins during TMEV infection, we compared the mRNA levels of α4 integrins in the CNS (brain and spinal cord) between naïve SJL/J and TMEV-IDD mice using real-time RT-PCR. The α4 integrins mRNA levels were significantly increased in the CNS (brain and spinal cord) of mice with TMEV-IDD at 40 dpi (n=7) compared with naïve SJL/J mice (n=6) (*p<0.05) (1.0 and 2.5, respectively) ( Fig. 1 ).
Antagonist of α4 integrin ameliorates the development of TMEV-IDD
To determine the effects of HCA3551, the orally active small molecule α4 integrin antagonist, on the development of TMEV-IDD, we treated mice with HCA3551 at the induction phase (from -3 to 14 dpi) or the effector phase (from 11 to 40 or 41 dpi) of the disease. The experimental design and the results of the effects of HCA3551 on the clinical course are summarized in Table 1 and Fig. 2 , respectively, including two independent experiments. TMEV-infected control animals (groups A and C treated with 0.5% methylcellulose as a vehicle at the effector phase) showed the typical course of TMEV-IDD. There were no significant differences in the clinical signs between control groups C and group D, which was treated with HCA3551 at the induction phase. However, the clinical signs of groups B and E, which were treated with HCA3551 at the effector phase, were significantly suppressed compared with the control groups (*p<0.05; from 14 to 40 dpi versus group A, at 21 dpi and from 32 dpi to 41 dpi versus group C) (**p<0.01; from 22 to 31 dpi versus group C), respectively. The mean maximum clinical scores (MMS) for the control groups were 2.5 in group A and 3.4 in group C, respectively. The MMS for group D mice treated with HCA3551 at the induction phase was 3.0. In contrast, the MMSs of group B and E mice, treated with HCA3551 at the effector phase, significantly decreased to 1.7 and 1.9 (**p<0.01 versus group A) (*p<0.05 versus group C), respectively. Assessments based on the mean cumulative clinical scores (MCSs) showed similar results. The MCSs of the control groups were 42.5 for group A and 61.0 for group C. The MCSs of the mice for group D were 52.1. However, the MCSs for groups B and E were significantly decreased to 28.0 and 37.2, respectively compared with methylcellulose-treated control mice (**p<0.01 versus group A) (*p<0.05 versus group C) respectively.
Histological findings
The representative mice were blindly selected from groups A and B (Table 1) 2A-2C) respectively. There was no significant intraobserver variation in the assessment of CD3, CD45R or CD68.
Treatment of mice with the orally active small molecule α4 integrin antagonist, HCA3551, in the effector phase decreases MNC infiltration into the CNS
The neuropathological changes in TMEV-IDD and MS are associated with the blood-brain barrier breakdown and infiltrates of MNCs (33) . Clinical disease in TMEV-IDD is correlated with the invasion of CNS through MNCs. To compare the levels of cellular infiltrations between the methylcellulose-treated control group and HCA3551-treated groups, the animals were sacrificed at 40 dpi in experiment 1 and 41 dpi in experiment 2. The infiltrating MNCs were isolated, using Percoll, from the CNS of TMEV-infected mice treated with HCA3551 or methylcellulose (n=17 and n=14, respectively). The isolated cells were calculated. The mean number of MNCs isolated from the CNS of the mice treated with methylcellulose was 1.89±0.1510 6 . In contrast, the mean number of MNCs isolated from the CNS of HCA3551-treated mice in the effector phase was significantly decreased to 1.03±0.1810 6 (**p<0.01) ( Fig. 3. 3A) . These results suggest that oral treatment with HCA3551, an antagonist against α4 integrin, suppressed disease development by inhibiting cellular infiltration to the CNS of TMEV-infected mice.
Administration of the orally active small molecule antagonist to α4 integrin, HCA3551, in the effector phase suppresses TNF-α-producing CD4 + cells and IFN-γ-producing CD8 + cells.
To examine the effect of HCA3551 in the effector phase on the number of pro-inflammatory cytokine-producing cells, we assessed the intracellular levels of IFN-γ-, TNF-α-, IL-4-, IL-10-and IL-17A-producing MNCs in the CNS at 40 dpi using flow cytometry after stimulation with VP2 [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] or VP3 159-166 peptides. The number of TNF-α-producing CD4 + T cells and IFN-γ-producing CD8 + T cells in the CNS was significantly decreased in mice treated with HCA3551 compared with the control mice (*p<0.05 and **p<0.01, respectively) ( Fig. 4B) . Notably, CD4 + T cells producing TNF-α and VP3 159-166 -specific CD8 + T cells were particularly reduced among T cells in the CNS of HCA3551-treated mice, as these T cells have been associated with the pathogenesis of TMEV-IDD (34, 35) .
Effects of the orally active small molecule α4 integrin antagonist, HCA3551, on viral persistence
To determine the effect of the orally active small molecule α4 integrin antagonist, HCA3551, on TMEV replication in the CNS, the viral mRNA levels in the CNS at 40 dpi were assessed by real-time RT-PCR ( Fig. 5 ). There was no significant difference in the TMEV mRNA levels between methylcellulose-treated control mice and mice treated with the orally active small molecule α4 integrin antagonist. These results suggest that the administration of orally active small molecule α4 integrin antagonist, HCA3551, during the effector phase does not affect TMEV replication. These results suggest that the inhibition of α4 integrin function might also affect the migration of protective T cells involved in the clearance of TMEV persistence in the CNS, in addition to the pathogenic T cells.
Discussion
The importance of α4 integrin in EAE is well established (20,36,37), but there are no reports on the importance and the role of α4 integrin in TMEV-IDD. Therefore, in the present study, we investigated the role of α4 integrin and the effects of the orally active small molecule α4 integrin antagonist, HCA3551, in the development of TMEV-IDD. HCA3551 is an orally active small molecule α4 integrin antagonist with an IC 50 value for VCAM-1 cell adhesion of 8.2 nM. Previous studies have suggested that T cells in inflamed CNS express high levels of active α4β1 integrin, and that the general expression of α4 integrin is increased on the surface of circulating monocytes in EAE (36, 38) . Moreover, compared with remission, the expression of α4 integrin was significantly up-regulated during relapse in relapsing-remitting MS patients (39) . In the present study, we demonstrated that the mRNA levels of α4 integrins were significantly increased in the CNS (brain and spinal cord) of mice with TMEV-IDD at 40 dpi compared with naïve SJL/J mice (*p<0.05) ( Fig.   1 ). α4 integrin is generally expressed on the surface of T cells, macrophages and circulating monocytes. Infiltrating cells to the CNS in TMEV-IDD are primarily macrophages, T cells and monocytes. Therefore, the up-regulated α4 integrin mRNA of primarily reflects infiltrated macrophages, T cells and monocytes. These findings indicate that α4 integrin might be closely associated with the development of TMEV-IDD.
Anti-α4 integrin antibodies or small molecule α4 integrin antagonists have been demonstrated as effective for the treatment of EAE (20- 22, 38) . However, to our knowledge, the effects of α4 integrin and its antagonist on the development of TMEV-IDD, which one of only a few infectious animal models of MS, have not yet been studied. The results of present study revealed that HCA3551 treatment significantly suppressed the development of TMEV-IDD (Fig. 2) . Furthermore, HCA3551 treatment dramatically decreased demyelination and the infiltration of MNCs into the CNS, consistent with a decrease in the number of TNF-α-producing CD4 + T cells and IFN-γ-producing CD8 + T cells (**p<0.01 and *p<0.05, respectively) (Fig. 4B ). This study is the first to demonstrate the efficacy of orally active small molecule α4 integrin antagonists in TMEV-IDD.
However HCA3551 is not effective in TMEV-IDD when administrated during the induction phase.
After TMEV inoculation (i.c.), initial viremia followed by persistent low-level CNS infection is observed (40) . TMEV infects neurons, glial cells and macrophages in the spinal cord (41) . This stage has been referred to as the 'induction phase'. During this phase, infiltration of macrophage and T cells into the CNS is low, and α4 integrin may not be important in this phase, thereby HCA3551 does not suppress TMEV-IDD when in the induction phase.
To further clarify the effects of the treatment of orally active small molecule α4 integrin antagonist, HCA3551, in TMEV-IDD, we measured the number of infiltrating cells, and the LIs for CD3, CD45R and CD68 antigen and assessed Th1, Th2 and Th17 responses in the CNS. The VCAM-1/α4β1 integrin ligand-receptor pair plays major roles in the recruitment of mononuclear leukocytes to inflammatory sites in vivo (19) . We showed that the administration of HCA3551 significantly suppressed the number of CNS inflammatory MNCs compared with administration of control vehicle methylcellulose (**p<0.01) ( Fig. 3. 3A ), suggesting that HCA3551 inhibits the infiltration of MNCs into the CNS through the inhibition of α4 integrin binding to VCAM-1.
Furthermore, the LIs for CD3, CD45R and CD68 antigen were significantly decreased in the CNS of mice treated with HCA3551 compared with mice treated with methylcellulose (*p<0.05) ( Fig. 3. 2A-2C). The numbers of TNF-α-producing CD4 + T cells and IFN-γ-producing CD8 + T cells in the CNS were significantly decreased and the numbers of IL-17A-producing CD4 + T cells in the CNS were decreased in mice treated with HCA3551 compared with control mice treated with methylcellulose ( Fig. 4B ). Previous studies have suggested that Th17 cells express lower amounts of α4 integrin than Th1 cells and Th1 cells preferentially infiltrate the spinal cord via an α4 integrin-mediated mechanism, whereas the entry of Th17 cells into the brain parenchyma occurs in the absence of α4 integrins but is dependent on αLβ2 expression (42) . Therefore, the differential expression of integrin molecules might result in the significant decrease in TNF-α-producing CD4 + T cells and IFN-γ-producing CD8 + T cells, but unaltered level of IL-17-producing CD4 + T cells compared with control mice. Thus, the significant suppression of TMEV-IDD was accompanied with the reduction of the LIs for the CD68 antigen, macrophages markers, and the reduced numbers of TNF-α-producing CD4 + cells and IFN-γ-producing CD8 + cells in the CNS of mice treated with HCA3551, because as these cell types have been implicated to play pathogenic roles in the disease development (13, 34, 35) . These results suggest that treatment with HCA3551 decreased the number of MNCs infiltrated into the CNS of TMEV-infected mice, theby suppressed the development of TMEV-IDD with decreasing the number of MNCs infiltrated into the CNS of TMEV-infected mice.
We examined whether the suppressive effect of HCA3551 treatment on TMEV-IDD might reflect the elimination of viral persistence. We assessed the levels of replication in the CNS of HCA3551-treated mice or methylcellulose-treated mice using real-time RT-PCR. The results showed that there were no significant differences in the mRNA levels of TMEV between methylcellulose-treated control mice and HCA3551-treated mice (Fig. 5 ). Thus, it seems that HCA3551 treatment reduced the development of TMEV-IDD without interfering viral persistence.
Consistently, viral levels might not necessarily be associated with the development of demyelinating disease in this model (43, 44) .
The results of the present study suggested that α4 integrin might play a critical role in the development of TMEV-IDD. Treatment with HCA3551 might ameliorate TMEV-IDD through the inhibition of α4 integrin binding to VCAM-1 accompanied a decrease in the number of MNCs in the CNS. HCA3551 also has a potential risk for PML. However, the pharmacological half-life of HCA3551 is 12 hours, which is much shorter than that of natalizumab (approximately 11 days) (28).
The potential advantage is that the early removal of this drug from the body after the onset of PML could lead to more favorable outcomes, but this is a hypothesis which needs further validation (45) . HCA3551 in methylcellulose twice a day via oral gavage per mouse from -3 to 14 dpi in the induction phase (group D) and from 11 to 41 dpi in the effector phase (group E). Clinical signs of TMEV-IDD were significantly suppressed in mice treated with HCA3551 in the effector phase (group E) from 21 to 41 dpi compared with control mice administered methylcellulose (*p<0.05; at 21 dpi and from 32 dpi to 41 dpi, **p<0.01; from 22 dpi to 31dpi). HCA3551 did not suppress TMEV-IDD when it was administered in the induction phase. Thus, the significant suppression of TMEV-IDD was observed only when HCA3551 was administered to mice with TMEV-IDD in the effector phase. The data are presented as the means ± SD. CD4 + and CD8 + T cell responses to viral epitopes at 40 dpi. Intracellular cytokine staining was performed on MNCs isolated from the CNS of mice administered methylcellulose or HCA3551 in the effector phase at 40 dpi. After stimulation with CD4 + (VP2 70-86 ) or CD8 + (VP3 159-166 ) T cell epitopes of TMEV (2 μM for each peptide) for 6 hours, the cells were triple-labeled with Table 1 .
Summary of effects of administration of HCA3551, orally active small antagonist molecules against α4 integrin, on TMEV-IDD. List of forward and reverse primers. 
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